Free Trial

Leo Wealth LLC Buys Shares of 9,982 Novartis AG (NYSE:NVS)

Novartis logo with Medical background

Leo Wealth LLC bought a new stake in Novartis AG (NYSE:NVS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 9,982 shares of the company's stock, valued at approximately $1,009,000.

Other large investors also recently bought and sold shares of the company. Frazier Financial Advisors LLC acquired a new position in Novartis in the fourth quarter valued at about $26,000. Richardson Financial Services Inc. acquired a new stake in shares of Novartis during the fourth quarter worth about $26,000. Operose Advisors LLC acquired a new stake in shares of Novartis during the third quarter worth about $28,000. Planned Solutions Inc. acquired a new stake in shares of Novartis during the fourth quarter worth about $31,000. Finally, AdvisorNet Financial Inc lifted its position in shares of Novartis by 480.0% during the fourth quarter. AdvisorNet Financial Inc now owns 348 shares of the company's stock worth $35,000 after purchasing an additional 288 shares in the last quarter. Institutional investors and hedge funds own 13.12% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on NVS shares. The Goldman Sachs Group started coverage on shares of Novartis in a research report on Thursday, May 30th. They set a "buy" rating and a $120.00 price target on the stock. BMO Capital Markets upped their target price on shares of Novartis from $114.00 to $116.00 and gave the stock a "market perform" rating in a research note on Wednesday, April 24th. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company's stock. According to data from, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $116.67.

Check Out Our Latest Stock Analysis on Novartis

Novartis Price Performance

Novartis stock remained flat at $104.93 during mid-day trading on Tuesday. 1,051,752 shares of the company's stock traded hands, compared to its average volume of 1,484,384. The stock has a market cap of $214.48 billion, a PE ratio of 14.16, a price-to-earnings-growth ratio of 1.62 and a beta of 0.58. Novartis AG has a one year low of $92.19 and a one year high of $108.78. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.71 and a current ratio of 0.90. The business has a 50-day moving average of $100.21 and a two-hundred day moving average of $100.73.

Novartis (NYSE:NVS - Get Free Report) last announced its quarterly earnings results on Tuesday, April 23rd. The company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.73 by $0.07. The company had revenue of $11.83 billion for the quarter, compared to analyst estimates of $11.50 billion. Novartis had a net margin of 31.33% and a return on equity of 32.15%. Equities analysts anticipate that Novartis AG will post 7.27 earnings per share for the current year.

Novartis Profile

(Free Report)

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

Recommended Stories

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

→ SHOCKING Gold Moves… (From Colonial Metals) (Ad)

Should you invest $1,000 in Novartis right now?

Before you consider Novartis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.

While Novartis currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks
Inside Pelosi’s Latest Stock Moves

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines